A well-known pharmaceutical company is expected to spend $1 billion in this field!

[pharmaceutical network enterprise news] it is reported that GSK is cooperating with the biopharmaceutical company imaging biotechnology GmbH to develop a new type of adoptive cell therapy for various tumor indications Under the terms of the deal, GSK will pay imatics about $50 million in advance of two initial plans Imatics is also eligible for various commercial milestone payments in excess of $550 million, as well as additional royalties In the future, GSK can choose to include more projects in cooperation For each project, images is eligible for options, milestones, and royalties As a result, the deal is likely to exceed $1bn and the amount of the deal could continue to increase if GSK chooses to include more target plans In fact, adoptive cell therapy is a new type of immunotherapy, which transfers the donor's lymphocytes to the receptor and enhances its cellular immune function Adoptive cellular immunity can be divided into two categories: specific and non-specific The former is to inject lymphocytes sensitized by known antigens into the receptor to obtain the cellular immunity to the antigen; the latter is to inject normal human lymphocytes not sensitized by special antigens into the receptor to obtain the cellular immunity to multiple antigens Because the process is time-consuming and expensive, many companies are working on so-called off the shelf cell therapies It is reported that the treatment will be based on T cells extracted from healthy patients and modified for specific cancer antigens in advance, which will take less time and reduce hospital costs In this regard, although the problems of car-t cell therapy continue, with the continuous innovation of scientists, car-t cell therapy will be more and more perfect, and the therapeutic effect will be better and better It is understood that GSK Public Service Co., Ltd., established in the UK on December 6, 1999, is a world leading research pharmaceutical and health care company, which is a combination of Glaxo Wellcome PLC and SmithKline Beecham PLC The company is committed to developing new products that are significantly better than the existing treatment options to help patients and governments, insurance companies or other third parties In fact, the cooperation between GSK and imatics is not special In recent years, GSK has been hoping to start from the emerging immunotherapy, to find a new way to reshape the status of tumor field For example, on September 6, 2019, GSK and innovax signed a global cooperation agreement, announcing that the two sides will jointly develop a new generation of HPV vaccine based on vantage's innovative antigen technology and GSK's adjuvant system This is the first time that Chinese vaccine companies have established a partnership with international vaccine companies to jointly develop and commercialize vaccines Data show that immunotherapy will account for half of cancer treatment by 2022 Among them, Novartis kymriah is priced at US $475000, which also shows the huge profit margin of car-t therapy to the developers At present, there are only two car-t therapies approved for market in the world, namely, kymriah of Novartis and yescarta of Gilead However, both of them are targeted at CD19 molecules However, a series of data of BCMA target are excellent, and the treatment field is different from CD19 The car-t Therapy Market Based on BCMA target is blank, and no drug has been approved at present As a result, GSK is currently actively seeking to acquire cancer or immune related transactions, which will focus on the purchase of early-stage drug licensing.